17-year-old Indian swimmer suspended 18 months for doping: A mistake from a prescription

I have followed doping cases in youth sports for 34 years. Not infrequently, I have seen talents extinguished not by intent to cheat, but by ignorance of the system. The latest incident from India is a painful example.

A 17-year-old Indian swimmer, who had qualified for the 2026 Asian Games in Japan, was unexpectedly removed from the national team and handed an 18-month suspension for testing positive for terbutaline — a beta-2 agonist commonly prescribed for asthma or bronchitis patients. His identity was not officially disclosed due to his minor status, but Indian media confirmed he is one of a pair of twins representing the country at international junior meets. His twin brother remains on the Asian Games team.

According to the Swimming Federation of India (SFI), the swimmer tested positive in February 2026. Initially, he was dropped from the Commonwealth Games roster, then from the Asian Games. The banned substance was terbutaline, a beta-2 agonist. According to the Mayo Clinic, terbutaline is used to treat asthma, emphysema, bronchitis, and other lung diseases — not a performance-enhancing drug.

But the problem lies in procedure. The swimmer stated he suffered smoke inhalation and took the medication under a doctor's prescription. He listed the substance on his doping control form. However, he did not apply for a Therapeutic Use Exemption (TUE) from the national anti-doping agency. Without a TUE, any detection of a banned substance, even unintentional, is considered a violation.

This is not a deliberate doping case, but an administrative mistake by a teenager and a medical team lacking knowledge of anti-doping rules.

Under WADA's standard rules, the penalty for a doping violation is four years. However, if the panel believes the athlete did not intentionally dope, the ban can be reduced to two years. Further reductions depend on the degree to which the athlete can provide a reasonable explanation for the unintentional use. In this case, the SFI held an expedited hearing last week, hoping the case could be dropped so he could race in Japan later this month. The final result was an 18-month suspension — a significant reduction from the maximum.

But for a 17-year-old, 18 months is a long time. This age is a golden period for physical and technical development. Missing the Asian Games, a springboard for young Asian talents, could cost him the chance to compete at the 2028 Olympics.

People look at the doping ban; I look at the system that failed to protect a young athlete.

This story is further complicated by the fact that his twin brother remains on the team. Indian media noted that distinguishing their competition results is difficult due to similar names. This raises questions about transparency: could there be a sample mix-up? However, the SFI insists the testing process was rigorous and the result accurate.

I have witnessed many similar cases in my career. In 2026, I wrote about a young Australian swimmer suspended for taking cold medicine containing a banned substance without checking the ingredients. In 2026, an Indian sprinter was dropped from the Commonwealth Games for using an over-the-counter painkiller containing a prohibited substance. These cases share a common thread: lack of doping education for athletes and medical staff.

India is the world's most populous country, but its sporting achievements are modest: only six medals (no gold) at the 2026 Paris Olympics. Notably, in recent years, India has led the world in anti-doping violations. This statistic reflects a reality: a rigid anti-doping system applied to athletes lacking knowledge leads to more unintentional violations than deliberate cheating.

The 2026 data vortex didn't just change how I read matches — it changed how I see people. That year, I built a performance prediction model for Melbourne Victory and discovered that the chance creation rate per minute was more important than dribble success. Similarly, instead of looking at the number of doping cases, we should look at the rate of athletes educated about TUEs, the rate of TUE applications denied, and the speed of case processing.

Back to the 17-year-old swimmer. He had qualified for two events at the Asian Games. That was years of hard training. All because of a dose of respiratory medication, everything collapsed. An 18-month ban may seem lenient, but for a teenager, it is a whole developmental period.

It took me three years to understand: the vortex is not to be feared, but to be ridden. The anti-doping system is the same. It should not be the enemy of athletes, but a tool to protect fairness. But to achieve that, education must start at the grassroots level. National sports federations need to train doctors, coaches, and athletes on TUE procedures, lists of prohibited substances, and consequences of violations.

This story is a wake-up call for all Asian sports. As countries invest heavily in high-performance sports, they must also invest proportionally in medical and legal support systems. Otherwise, young talents will continue to have their futures stolen by unfortunate mistakes.

Numbers speak. But numbers must also be placed in context. The 18-month ban, the substance terbutaline, the missed Asian Games — all are data. But behind them is a 17-year-old boy with dreams, a family, and a twin brother sharing the same passion. That is the real story.